We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Teladoc (TDOC - Free Report) closed at $23.92, marking a -1.36% move from the previous day. This change lagged the S&P 500's 0.8% loss on the day. Meanwhile, the Dow lost 0.3%, and the Nasdaq, a tech-heavy index, lost 0.03%.
Coming into today, shares of the telehealth services provider had lost 15.92% in the past month. In that same time, the Medical sector lost 3.06%, while the S&P 500 lost 5.13%.
Teladoc will be looking to display strength as it nears its next earnings release, which is expected to be October 26, 2022. In that report, analysts expect Teladoc to post earnings of -$0.59 per share. This would mark a year-over-year decline of 11.32%. Meanwhile, our latest consensus estimate is calling for revenue of $609.14 million, up 16.77% from the prior-year quarter.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$61.43 per share and revenue of $2.4 billion. These results would represent year-over-year changes of -4518.8% and +18.1%, respectively.
Investors might also notice recent changes to analyst estimates for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.4% lower within the past month. Teladoc currently has a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Teladoc (TDOC - Free Report) closed at $23.92, marking a -1.36% move from the previous day. This change lagged the S&P 500's 0.8% loss on the day. Meanwhile, the Dow lost 0.3%, and the Nasdaq, a tech-heavy index, lost 0.03%.
Coming into today, shares of the telehealth services provider had lost 15.92% in the past month. In that same time, the Medical sector lost 3.06%, while the S&P 500 lost 5.13%.
Teladoc will be looking to display strength as it nears its next earnings release, which is expected to be October 26, 2022. In that report, analysts expect Teladoc to post earnings of -$0.59 per share. This would mark a year-over-year decline of 11.32%. Meanwhile, our latest consensus estimate is calling for revenue of $609.14 million, up 16.77% from the prior-year quarter.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$61.43 per share and revenue of $2.4 billion. These results would represent year-over-year changes of -4518.8% and +18.1%, respectively.
Investors might also notice recent changes to analyst estimates for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.4% lower within the past month. Teladoc currently has a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.